High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa
- 31 December 2010
- journal article
- research article
- Published by Elsevier BV in Molecular Genetics and Metabolism
- Vol. 101 (4), 338-345
- https://doi.org/10.1016/j.ymgme.2010.08.009
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infantsMolecular Genetics and Metabolism, 2010
- Enzyme analysis for Pompe disease in leukocytes; superior results with natural substrate compared with artificial substratesJournal of Inherited Metabolic Disease, 2009
- Long-term Efficacy and Safety of Laronidase in the Treatment of Mucopolysaccharidosis IPEDIATRICS, 2009
- Clinical features of late‐onset Pompe disease: A prospective cohort studyMuscle & Nerve, 2008
- Reduced α-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry diseaseMolecular Genetics and Metabolism, 2008
- Chinese hamster ovary cell-derived recombinant human acid α-glucosidase in infantile-onset Pompe diseaseThe Journal of Pediatrics, 2006
- Standardisation of spirometryEuropean Respiratory Journal, 2005
- Enzyme therapy of gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodiesBlood Cells, Molecules, and Diseases, 2003
- Muscular weakness assessment: Use of normal isometric strength dataArchives of Physical Medicine and Rehabilitation, 1996